Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

Core Insights - The primary endpoint indicates that orforglipron significantly reduced A1C levels by 2.2% compared to a 1.4% reduction with oral semaglutide at the highest doses [1] - Participants receiving the highest dose of orforglipron experienced an average weight loss of 19.7 lbs, which is approximately 9.2% of their body weight [1]